Final results from the prospective phase III WSG-ARA trial: Impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 75-80

  Nitz, U ^a,b   Gluz, O ^a,b   Zuna, I ^b   Oberhoff, C ^c,d   Reimer, T ^e   Schumacher, C ^f   Hackmann, J ^g   Warm, M ^h,i   Uleer, C ^j   Runde, V ^k   Dunnebacke J ^l   Belzl, N ^m   Augustin, D ⁿ   Kates, R E ^b   Harbeck, N ^b,o  

^a Evangelical Hospital Bethesda   (Germany)

^b West German Study Group   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Department of Diagnostic Radiology and Nuclear Medicine   (Germany)

^e Department of Neurology University Medicine Rostock   (Germany)

^f St Elisabeth Hospital   (Germany)

^g Marien Hospital Witten   (Germany)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ Breast Center   (Germany)

^j Praitice for Gynaecology and Oncology   (Germany)

^k Wilhelm Anton Hospital   (Germany)

^l Gynaecology Hospital Marienhof   (Germany)

^m Department of Cardiology and Angiology   (Germany)

ⁿ Mamma Center Ostbayern Clinics Deggendorf   (Germany)

^o UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Adjuvant chemotherapy; Anemia; Breast cancer; Epoetin; Safety

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERROUS SULFATE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY CANCER; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

ADJUVANT CHEMOTHERAPY; ANEMIA; BREAST CANCER; EPOETIN; SAFETY;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84900436343     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt505     Document Type: Article

References (26)

1. Littlewood TJ, Bajetta E, Nortier JWR et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
2. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
3. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315.
4. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
5. Untch M, von Minckwitz G, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 2011; 22: 1999-2006.
6. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
7. Overgaard J, Hoff CM, Hansen HS et al. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial. J Clin Oncol 2009; 27: 15s (suppl; Abstr 6007).
8. Machtay M, Pajak TF, Suntharalingam M et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007; 69: 1008-1017.
9. Blohmer J-U, Paepke S, Sehouli J et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol 2011; 29: 3791-3797.
10. Delarue R, Haioun C, Coiffier B et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. ASCO Meeting Abstracts 2011; 29: 9048.
11. Engert A, Josting A, Haverkamp H et al. Epoetin alfa in patients with advancedstage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010; 28: 2239-2245.
12. Wilkinson PM, Antonopoulos M, Lahousen M et al. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 2006; 94: 947-954.
13. Steensma DP, Loprinzi CL. Erythropoietin Use in cancer patients: a matter of life and death? J Clin Oncol 2005; 23: 5865-5868.
14. Untch M, Fasching PA, Konecny GE et al. PREPARE Trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/ cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer-results at the time of surgery. Ann Oncol 2011; 22: 1988-1998.
15. Moebus V, Jackisch C, Schneeweiss A et al. Adding epoetin alfa to intense dosedense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105: 1018-1026.
16. Swain SM, Tang G, Geyer CE et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 2013; 31: 3197-204.
17. Aapro M, Jelkmann W, Constantinescu SN et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106: 1249-1258.
18. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-1220.
19. Hedenus M, Vansteenkiste J, Kotasek D et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005; 23: 6941-6948.
20. Seidenfeld J, Piper M, Flamm C et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-1214.
21. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-1234.
22. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit study group. J Clin Oncol 1998; 16: 3412-3425.
23. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
24. Cella D, Kallich J, McDermott A et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15: 979-986.
25. Ross SD, Elaine Allen I, Henry DH et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapyinduced anemia: a systematic review of the literature. Clin Ther 2006; 28: 801-831.
26. Minton O, Richardson A, Sharpe M et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100: 1155-1166.